Publications 2014 – 2015

Adams S, Ehrlich R, Baatjies R, van Zyl-Smit RN, Said-Hartley Q, Dawson R, Dheda K. Incidence of occupational latent tuberculosis infection in South African healthcare workers. Eur Respir J 2015. Feb 19. pii: ERJ-01384-2014.
Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med 2015; 3: 719-728.
Allwood B, van Zyl-Smit RN. Chronic obstructive pulmonary disease in South Africa: Under-recognised and undertreated. 2015. South African Medical Journal 2015;105(9):785. DOI:10.7196/samj.9971
Viviers PJ, van Zyl-Smit RN. Chronic obstructive pulmonary disease – diagnosis and classification of severity. 2015. South African Medical Journal 2015;105(9):786. DOI:10.7196/samj.9972
van Zyl-Smit RN, Naidoo J, Wainwright H, Said-Hartley Q, Davids M, Goodman H, Rogers S, Dheda K et al. HIV associated Lymphocytic Interstitial Pneumonia: a clinical, histological and radiographic study from an HIV endemic resource-poor setting. BMC pulmonary medicine 2015; 15(1): 38.
Bernstein DI, Bateman ED, Woodcock A, Toler WT, Forth R, Jacques L, Nunn C, O'Byrne PM. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. J. Asthma 2015, in press.
Amaral AFS, Jithoo A, Coton S, Kato B, Tan WC, Studnicka M, Janson C, Gislason T, Mannino D, Bateman ED, Buist S, Burney PGJ, for the BOLD Collaborative Research Group. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J, 2015. In press.
Hall IP, Fowler AV, Gupta A, Tetzlaff K, Nivens MC, Sarno M, Finnigan HA, Bateman ED, Sutherland ER. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol and Therapeutics, 2015, in press.
Bateman ED, Esser D, Chirila C, Fernandez M, Fowler A, Moroni-Zentgraf, FitzGerald JM. Magnitude of effect of asthma treatments on AQLQ and ACQ: systematic review and network meta-analysis. J Allergy Clin Immunol, 2015, in press.
Buhl R, Abrahams R, Bateman ED, Bjermer L, Derom E, Ferguson G, Fležar M, Grönke L, Hamilton A, Hébert J, Korducki L, Maltais F, McGarvey L, Pizzichini L, Reid J, Tetzlaff K, Veale A, Watz H, Waitere-Wijker S. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J, 2015. DOI: 10.1183/09031936.00136014
Kerstjens HAM, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, Engel M, Bour L, Verkleij CB, Moroni-Zentgraf P, Bateman ED. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respiratory Medicine 2015; DOI:
Chapman KR, Bateman ED, Chen H, Hu H, Fogel R, Banerji D. QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies. J COPD F. 2015. doi:
Castro M, Zangrilli J, Wechsler ME, Bateman ED, BrusselleGG, Bardin P, Murphy K, Maspero JF, O’Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophils: results from two, multicentre parallel, double-blind, placebo controlled trials. Lancet Respiratory 2015, in press.
Folb N, Timmerman V, Levitt NS, Steyn K, Bachmann MO, Lund C, Bateman ED, Lombard C, Gaziano TA, Zwarenstein M, Fairall L. Multimorbidity, control and treatment of non-communicable diseases among primary care attenders in the Western Cape, South Africa. S Afr Med J, 2015, in press.
Hohlfeld JM, FurtwaenglerA, Könen-Bergmann M, Wallenstein G, Walter B, Bateman ED. Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomized clinical trials. Int J Clin Pract. 2015 Jan;69(1):72-80. doi: 10.1111/ijcp.12596
Thomas DM, Bateman ED. Asthma attacks- how can we reduce the risks? Editorial. NPJ Prim Care Respir Med, 2015; Jan 8;25:14105. doi: 10.1038/npjpcrm.2014.105. PMID: 25569849
van Zyl-Smit RN, Binder A, Meldau R, Semple PL, Evans A, Smith P, et al. Cigarette smoke impairs cytokine responses and BCG containment in alveolar macrophages. Thorax,/span>. 2014.;69:363-370.
Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, Obrien, JA, Smith C, Abdool-Gaffar MS, Emanual S, Esterhuizen TM Irusen EM. Efficacy of varenicline ancombined with nicotine replacement therapy vs varenicline alone for smoking cessation, A randomised clinical trial. JAMA 2014;312(2)155-161
Schraufnagel DE, Blasi F, Drummond B, Lam DCL, Rosen MJ, Sanores R, van Zyl-Smit RN. Electronic Cigarettes: A position statement of the Forum of International Respiratory Societies. Am J Respir Crit Care Med. 2014 190,6,611-618
Tagmouti S, Slater M, Benedetti A, Kik S, Banaei N, Cattamanchi A, Metcalfe J, Dowdy D, van Zyl-Smit RN, Dendukuri N, Pai M, Denkinger C. Reproducibility of interferon gamma release assays: a systematic review. Annals of ATS 2014, 11(8)1267-1276.
Meldau R, Peter J, Theron G, Calligaro G, Allwood B, Symons G, Khalfey H, Ntombenhle G, Govender U, Binder A, van Zyl-Smit R, Dheda K. Comparison of same day diagnostic tools including Gene Xpert and unstimulated IFN-gamma for the evaluation of pleural tuberculosis: a prospective cohort study. BMC pulmonary medicine 2014; 14: 58.
Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, Caracta C, Gil EG, Leselbaum A. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014 Nov 18;14:178. doi: 10.1186/1471-2466-14-178.
Bleecker ER, Lotvall J, O’Byrne PM, Woodcock A, Busse WW, Kerwin EM, Forth R, Medley HV, Nunn C, Jacques L, Bateman ED. Fluticsone furoate-vilanterol 100-25 mcg compared with fluticasone furoate in asthma: a randomized trial. J Allergy Clin Immunol Pract. 2014;2(5):553-561.doi:10:1016/j.jaip.2014.02.10. PMID:25213048
Sodhi S, Banda H, Kathyola D, Joshua M, Richardson F, Mah E, MacGregor H, Kanike E, Thompson S, Fairall L, Bateman E, Zwarenstein M, Schull MJ. Supporting Middle-Cadre Health Care Workers in Malawi: Lessons Learned During Implementation of the PALM PLUS Package. BMC Health Serv Res. 2014;14 Suppl 1:S8. Doi:10:1186/1472-6963-14-S1-S8) PMID 25080192
Bateman ED, Buhl R, O’Byrne PM, Humbert M, Reddel HK, Sears MR, Jenkins C, Harrison TW, Quirce S, Peterson S, Eriksson G. Development and validation of a novel risk score for asthma exacerbations, the RSE. J Allergy Clin Immunol. 2014 Sep 22. pii: S0091-6749(14)01187-7. doi: 10.1016/j.jaci.2014.08.015.
Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, et al. Integrated care pathways for airways diseases (AIRWAYS-ICPs). Eur Respir J. 2014; 44(2):304-23. doi: 10.1183/09031936.00014614. PMID: 24925919
Lötvall J, Bateman ED, Busse WW, O’Byrne PM, Woodcock A, Toler WT, Jacques L, Goldfrad C, Bleecker ER. Comparison of vilanterol, a novel long-standing beta2-agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. J Negat Results Biomed. 2014;13:9. Doi:10.1186/1477-5751-13-9. PMID:24928338.
Bateman ED. Patient adherence in asthma. The Last Frontier. Invited editorial. J Allergy Clin Immunol. 2014 Dec;134(6):1269-70. doi: 10.1016/j.jaci.2014.08.004. Epub 2014 Sep 23.
Jones PW, Lamarca R, Chuecos F, Singh D, Agusti A, Bateman ED, de Miguel G, Caracta C, Garcia Gil E. Characterisation and impact of reported and unreported exacerbations: Results from ATTAIN. Eur Respir J. 2014 Nov;44(5):1156-65. doi: 10.1183/09031936.00038814.
Koegelenberg KFN, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O’Brien JA, Smith C, Abdool-Gaffar MS, Emanuel S, Esterhuizen TM, Irusen EM. Efficacy of Varenicline Combined with Nicotine Replacement Therapy vs Varenicline Alone for Smoking Cessation: a randomized clinical trial. JAMA. 2014;312:155-61. Doi,:10:1001/jama.2014.7195. PMID:25005652.
O'Byrne PM, Woodcock A, Bleecker ER, Bateman ED, Lötvall J, Forth R, Medley H, Jacques L, Busse WW. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. Respir Res. 2014 Aug 11;15:88. doi: 10.1186/s12931-014-0088-z.PMID: 25108545
Busse WW, Bateman ED, O’Byrne P, Lotval J, Woodcock AA, Medley HV, Forth R, Jacques LA. Once-daily fluticasone furoate 50mcg in mild to moderate asthma: a 24-week placebo-controlled randomized trial, Allergy. 2014, Nov;69(11):1522-30. doi: 10.1111/all.12480. Epub 2014 Aug 22. PMID: 25040613.
Woodcock A, Lötvall J, Busse WW, Bateman ED, Stone S, Ellsworth A Jacques L. Efficacy and safety of fluticasone furoate 100 ug and 200 ug once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. BMC Pulm Med 2014;14:113. Doi:10.1186/1471-2466-14-113. PMID:25007865
Willson J, Bateman ED, Pavord I, Lloyd A, Krivasi T, Esser D. Cost-effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting beta-agonists. Appl Health Econ Health Policy. 2014;12:447-59. doi:10.1007/s40258-014-0107-8.
Yorgancioglu A, Cruz AA, Bousquet J, Khaltaev N, Mendis S, Chuchalin A, Bateman ED, Camargos P, Chavannes NH, Bai C, Deleanu D, Kolek V, Kuna P, Laurendi G, Masjedi MR, Mele S, Mihaltan F, Pinto JR, Samolinski B, Scalera G, Sooronbaev T, Tageldin MA, Tuyetlan le T, Yusuf O, Akdis C, Baigenzhin A, Cagnani CB, Fletcher M,Gemicioglu B, Muhammed Y, Sagra H, To T, Wagner AH. The Global Alliance against Respiratory Diseases (GARD) Country Report. Prim Care Respir J. 2014; 23:98-101.
Bateman ED, Donald A Mahler DA, Vogelmeier CF, Wedzicha JA, Patalano F, Banerji D. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med. 2014;8(3):357-79. doi: 10.1586/17476348.2014.910457. PMID:24802656
Price D, Bateman ED, Chisholm A, Papadopoulos NG, Bosnic-Anticevich, Pizzichini E, Hillyer EV, Buist S. Complementing the Randomized Controlled Trial Evidence Base: Evolution not Revolution. Ann Am Thorac Soc. 2014; 11, Supplement 2, pp S92–S98.
Jones RCM, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Bateman ED. Opportunities to Diagnose Chronic Obstructive Pulmonary Disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med, 2014; 2:267-76.
Calligaro GL, Raine RI, Bateman ME, Bateman ED, Cooper CB. Comparing dynamic hyperinflation and associated dyspnea induced by metronome-paced tachypnea versus incremental exercise. COPD: Journal of Chronic Obstructive Pulmonary Disease 2014;11:105-112. PMID: 24152211
Chapman KR, Beeh K-M, Beier J, Bateman ED, D’Urzo AD, Nutbrown R, Henley M, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med, 2014,14:4 DOI:10.1186/1471-2466-14-4.
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk P, Adcock IM, Bateman E, Bel E, Bleecker E, Boulet L-P, Brightling C, Chanez P, Dahlen S-E, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour N, Mauad T, Sorkness R, Teague G. International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma. Eur Respir J, 2014; 43:343-373. DOI:10.1183/09031936.00202013.
Lötvall J, Bleecker ER, Busse WW, O’Byrne PM, Woodcock A, Kerwin EM, Stone S, Forth R, Jacques L, Bateman ED. Efficacy and safety of fluticasone furoate 100μg once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomized trial. Respir Med. 2014 Jan;108(1):41-9. doi: 10.1016/j.rmed.2013.11.009. Epub 2013 Nov 19. PMID: 24295556.
Shamyshkin Y, Kotchie RW, Mörk AC, Briggs AH, Bateman ED. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur J Health Econ. 2014 Jan;15(1):69-82. doi: 10.1007/s10198-013-0456-5. Epub 2013 Feb 8. PMID: 23392624.
Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014 Oct 2;371(14):1285-94. doi: 10.1056/NEJMoa1407154. Epub 2014 Sep 8. PMID: 25196117
Cooper CB, Calligaro GL, Quinn MM, Eshaghian P, Coskun F, Abrazado M, Bateman ED, Raine RI. Determinants of dynamic hyperinflation during metronome-paced tachypnea in COPD and normal subjects. Respir Physiol Neurobiol. 2014 Jan 1;190:76-80. doi: 10.1016/j.resp.2013.08.002. Epub 2013 Aug 27. PMID: 23994176.
Burney P, Jithoo A, Kato B, Janson C, Mannino D, Nizankowska-Mogilnicka E, Studnicka M, Tan W, Bateman E, Koçabas A, Vollmer WM, Gislason T, Marks G, Koul PA, Harrabi I, Gnatiuc L, Buist S; for the Burden of Obstructive Lung Disease (BOLD) Study. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty – a BOLD analysis. Thorax. 2014;69:465-473.